HERON THERAPEUTICS, INC. DE (HRTX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Net product sales | 37,200 | 38,903 | 32,810 | |
| Cost of product sales | 9,857 | 8,457 | 9,458 | |
| Gross profit | 27,343 | 30,446 | 23,352 | |
| Sales and marketing | 11,575 | 12,311 | 10,972 | |
| Research and development | 2,934 | 2,279 | 4,465 | |
| General and administrative | 14,471 | 12,702 | 12,373 | |
| Total operating expenses | 28,980 | 27,292 | 27,810 | |
| (loss) income from operations | -1,637 | 3,154 | -4,458 | |
| Other expense, net | -744 | -519 | -390 | |
| Net (loss) income | -2,381 | 2,635 | -4,848 | |
| Unrealized loss on short-term investments | -2 | -12 | 48 | |
| Comprehensive (loss) income | -2,383 | 2,623 | -4,800 | |
| Earnings per share, basic | -0.02 | 0.02 | -0.03 | |
| Earnings per share, diluted | -0.02 | 0.01 | -0.03 | |
| Weighted average common shares outstanding, basic | 154,020,000 | 153,490,000 | 152,830,000 | |
| Weighted average common shares outstanding, diluted | 154,020,000 | 196,921,000 | 152,830,000 | |